GG News Bureau
New Delhi, 31st July. A groundbreaking study has unveiled new cancer treatment pathways by investigating the role of Kindlins—adapter proteins central to cellular signaling pathways. Researchers from the S. N. Bose National Centre for Basic Sciences in Kolkata, supported by the Department of Science and Technology (DST), explored the impact of these proteins on various cancers, revealing their potential as therapeutic targets.
Kindlins, which are integral to transmitting external mechanical signals into biochemical reactions within cells, play a crucial role in maintaining cellular homeostasis. Mutations in Kindlins, influenced by carcinogens such as nicotine and UV rays, can disrupt cellular balance and contribute to cancer progression.
The research team, led by Debojyoti Chowdhury and guided by Prof. Shubhasis Haldar, analyzed data from 10,000 patients across 33 cancer types from The Cancer Genome Atlas. Their findings highlight that Kindlin 1 affects the immune microenvironment in breast cancer, while Kindlin 2 regulates cancer-specific metabolic processes and the Hippo signaling pathway, which influences cell migration and invasion.
The study, published in Communications Biology, emphasizes the importance of Kindlins in tumor progression, metastasis, and epithelial-mesenchymal transition (EMT)—a process where cancer cells become more mobile and invasive. By exploring the interactions of Kindlin proteins with each other and other cellular components, the research offers insights into their roles in cancer biology and potential therapeutic targets.
The study’s findings underscore Kindlins as promising candidates for mechano-modulatory cancer therapies, potentially addressing challenges such as chemoresistance and tumor relapse. This research opens new avenues for cancer treatment, offering hope for innovative therapeutic strategies in the ongoing battle against the disease.
Comments are closed.